Replies to post #494176 on Anavex Life Sciences Corp (AVXL)

[Guzzi62]

Sorry, I stand corrected.

ATTENTION-AD will be conducted in parallel with the Phase 2b/3 ANAVEX®2-73-AD-004 study.

All patients who participate in the Phase 2b/3 ANAVEX®2-73-AD-004 study will be eligible to participate also in the ATTENTION-AD study under a voluntary open label extension protocol.

“This is an important development as the patients who have completed the main study, ANAVEX2-73-AD-004, are consistently expressing the wish to gain ongoing access to this investigational therapy” says A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator for both studies.

Surely Prof. Macfarlane had full access to all data, being the lead investigator?

Dr Marwan is the last name in the journal.

https://www.anavex.com/post/anavex-life-sciences-announces-attention-ad-anavex-2-73-extension-clinical-study-in-early-alzheimer

[sab63090]

Thanks, George!!!.....I am just about caught up with the posts and now saw your post!

Appreciate the clarification on the lead writer...both of these are well informed and I doubt either of them would mislead the rest of the peer review group.

So that makes two scientists who would likely NOT risk ruining their reputation; and for me that is worth a lot!